✦ LIBER ✦

195 Clinical experience with antiangiogenic targeting in ovarian cancer

✍ Scribed by M.A. Bookman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical experience with topotecan in re

✍ Thomas J Herzog 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Collateral damage: toxic effects of targ

✍ Rebecca L Stone; Anil K Sood; Robert L Coleman 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 220 KB

Thalidomide, an antiangiogenic agent wit

✍ S.S.W. Ng; M. Brown; W.D. Figg 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 55 KB

PRO: Patients With Recurrent Ovarian Can

✍ Boruta, David; Farley, John; Birrer, Michael J. 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 861 KB

PRO: Patients with Recurrent Ovarian Can

✍ David Boruta; John Farley; Michael J. Birrer 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 241 KB

A clinical experience of single agent be

✍ Emile, George; Chauvenet, Laure; Tigaud, Jean-Marie; Chidiac, Jean; Pujade Laura 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 257 KB